Last updated: July 31, 2026
Enflurane is a legacy inhalational anesthetic with no meaningful current clinical-development program, no active U.S. market presence, no relevant patent exclusivity, and no identifiable commercial growth pathway. The drug has been displaced by isoflurane, sevoflurane, desflurane, intravenous propofol, and modern multimodal anesthesia. Its market value is now limited to residual use in selected countries, institutional stock, and historical or academic research.
What is the current clinical-trial status of enflurane?
Enflurane has no established active clinical-trial pipeline for a new indication, reformulation, or expanded use. The drug is a mature anesthetic whose clinical development occurred primarily before the modern ClinicalTrials.gov era.
A ClinicalTrials.gov search for “enflurane” identifies historical studies and comparative anesthesia research rather than an active sponsor-led development program for a new product or indication. The studies generally compare enflurane with other inhalational anesthetics or evaluate perioperative outcomes. They do not establish a current regulatory development strategy.[1]
| Clinical-development category |
Current assessment |
| New drug development |
None identified |
| New indication trials |
None identified |
| Phase 2 or Phase 3 commercial program |
None identified |
| Pediatric expansion program |
No active program identified |
| Combination product development |
None identified |
| Drug-device development |
None identified |
| Biosimilar or follow-on biologic activity |
Not applicable |
| Regulatory priority designation |
None identified |
What clinical uses were historically studied?
Historical studies evaluated enflurane for:
- General anesthesia during surgery
- Induction and maintenance of anesthesia
- Hemodynamic effects
- Recovery time and postoperative complications
- Comparative performance against halothane, isoflurane, sevoflurane, and intravenous anesthetics
- Obstetric, pediatric, cardiovascular, and neurosurgical anesthesia
The U.S. prescribing information describes enflurane as a volatile inhalational anesthetic for induction and maintenance of general anesthesia. Its clinical profile includes dose-dependent respiratory and cardiovascular depression, potentiation of neuromuscular blockade, and electroencephalographic changes associated with seizure-like activity at higher concentrations or in susceptible patients.[2]
Why is enflurane no longer an active development asset?
Enflurane has several commercial and clinical disadvantages:
- It can produce central nervous system excitation and seizure-like electroencephalographic activity, particularly at high concentrations or with hypocapnia.
- It is associated with metabolism that produces inorganic fluoride, creating historical concern about renal effects.
- It has slower recovery characteristics than some modern alternatives.
- Its environmental and handling profile is less attractive than newer anesthetic strategies.
- Hospitals have shifted toward sevoflurane, isoflurane, desflurane, and propofol-based anesthesia.
- Anesthesia practice increasingly uses short-acting intravenous agents and regional or multimodal techniques.
The product’s known limitations reduce the commercial value of conducting new trials unless a sponsor identifies a specific low-cost or regional-use niche.
What is the FDA regulatory status of enflurane?
Enflurane was approved in the United States as Ethrane, historically marketed by Ohio Medical Products and associated with Abbott Laboratories. The product was regulated as a prescription inhalational anesthetic.
The U.S. product is no longer a significant marketed anesthetic. Historical FDA labeling remains relevant for pharmacology, dosing, contraindications, warnings, and adverse reactions, but the existence of historical labeling does not indicate an active commercial development program.[2]
| FDA-related issue |
Enflurane status |
| Original U.S. product |
Ethrane |
| Active U.S. commercial franchise |
No meaningful active franchise identified |
| New drug development |
None identified |
| Current FDA exclusivity |
None |
| Orphan-drug exclusivity |
None |
| Pediatric exclusivity |
None |
| Breakthrough designation |
None |
| Priority review |
None |
| REMS |
None identified |
| Current commercial regulatory momentum |
None |
What is the Orange Book status of enflurane?
Enflurane does not have a commercially relevant current Orange Book patent or exclusivity position. The product’s original composition and use rights are historical and expired.
The FDA Orange Book is primarily relevant to approved products with listed patents and regulatory exclusivity that can affect abbreviated new drug application timing. Enflurane has no meaningful current Orange Book barrier to generic entry.[3]
What patents protect enflurane?
No live composition-of-matter patent is expected to protect enflurane in the United States or other major pharmaceutical markets. Enflurane was developed and commercialized decades ago, placing any original patent rights well beyond the ordinary patent term.
| IP category |
Current commercial relevance |
| Enflurane composition patent |
Expired |
| Basic anesthetic-use patents |
Expired |
| Formulation patents |
No material active estate identified |
| Device patents |
Potentially relevant only to equipment, not the molecule |
| Manufacturing patents |
Any historic protection is generally expired or non-blocking |
| Orange Book-listed patents |
No meaningful current listing identified |
| Patent litigation |
No material current litigation identified |
| Paragraph IV activity |
Not commercially relevant |
| Patent settlement agreements |
None identified |
Are formulation patents a barrier to enflurane entry?
No material formulation-patent barrier is apparent. Enflurane is administered as a volatile liquid vaporized through anesthesia equipment. It does not require a complex injectable formulation, controlled-release system, biologic manufacturing process, or specialized delivery technology.
Potential intellectual-property rights could exist around:
- Vaporizer design
- Packaging and storage
- Calibration systems
- Anesthesia machines
- Environmental capture or scavenging systems
Those rights would generally concern equipment or packaging rather than the active pharmaceutical ingredient. They would not recreate market exclusivity for enflurane itself.
Are manufacturing patents a barrier?
Manufacturing is unlikely to be blocked by active enflurane patents. The principal barriers are regulatory, technical, and commercial:
- Demonstrating chemical identity and purity
- Controlling residual impurities
- Validating container-closure compatibility
- Establishing stability in volatile packaging
- Demonstrating vaporizer compatibility
- Meeting current good manufacturing practice requirements
- Generating current safety and quality documentation
- Establishing a commercially viable supply chain
For a low-volume legacy anesthetic, these costs can exceed the expected return even when the molecule is legally unencumbered.
When did enflurane lose exclusivity?
Enflurane lost practical exclusivity many years ago. Any U.S. patent protection associated with the original molecule or early commercial product expired decades before the current market period.
The relevant distinction is between legal freedom to manufacture and commercial viability. Enflurane is legally open to generic development in the absence of a blocking patent, but a sponsor still would need an FDA-compliant approval pathway and a reliable market. The absence of patent protection has not created a meaningful generic market because demand is limited and competing anesthetics are well established.
Which companies are challenging enflurane?
No material current Paragraph IV challenger group has emerged around enflurane. This is consistent with the product’s commercial status:
- There is no significant branded U.S. product to challenge.
- There is no valuable remaining patent estate.
- The addressable market is small.
- Hospitals have established substitutes.
- The economics of an abbreviated approval filing are weak.
The more relevant competitive activity is substitution by manufacturers of other inhalational anesthetics, including isoflurane, sevoflurane, and desflurane, and by suppliers of propofol and other intravenous anesthetics.
How does enflurane compare with competing anesthetics?
Enflurane is commercially disadvantaged against both inhaled and intravenous alternatives.
| Product |
Active ingredient |
Main commercial position |
Relative status versus enflurane |
| Ethrane |
Enflurane |
Legacy inhalational anesthetic |
Obsolete or marginal |
| Forane and generics |
Isoflurane |
Established low-cost inhalational anesthetic |
Stronger hospital position |
| Ultane and generics |
Sevoflurane |
Widely used inhalational anesthetic with favorable induction profile |
Stronger clinical adoption |
| Suprane and generics |
Desflurane |
Rapid emergence profile, though environmental concerns affect use |
Greater historical market presence |
| Diprivan and generics |
Propofol |
Dominant intravenous anesthetic for induction and maintenance strategies |
Major substitute |
| Halothane |
Halothane |
Legacy anesthetic |
Also largely displaced |
What technical disadvantages affect market adoption?
Enflurane’s pharmacologic limitations are central to its decline. The historical label warns about respiratory depression, hypotension, cardiac effects, malignant hyperthermia susceptibility, hepatic effects, and seizure-like activity.[2]
Modern anesthetic selection often prioritizes:
- Predictable onset and recovery
- Lower postoperative nausea
- Better control of hemodynamics
- Reduced metabolism
- Compatibility with ambulatory surgery
- Lower environmental impact
- Broad availability from multiple suppliers
Enflurane does not provide a clear advantage on these parameters.
What is the current enflurane market size?
A reliable standalone global revenue figure is not publicly established. Enflurane is generally absent from current major pharmaceutical market reports because it is no longer a material commercial category in North America, Western Europe, Japan, or other high-value anesthesia markets.
The global market is best characterized as:
| Market segment |
Current outlook |
| United States |
De minimis or no meaningful commercial market |
| Western Europe |
De minimis |
| Japan |
De minimis |
| China |
Limited, if available through legacy or local channels |
| India and other emerging markets |
Possible residual institutional use |
| Low-resource markets |
Potential use where legacy equipment and supply determine selection |
| Academic research |
Small and noncommercial |
| Global branded revenue |
Not material |
Enflurane revenue should not be confused with the broader inhalational-anesthetics market. Growth in the broader category does not imply growth for enflurane. Current market expansion is concentrated in newer or more widely available agents, particularly sevoflurane and generic isoflurane, while propofol captures substantial intravenous anesthesia demand.
What is the enflurane market forecast through 2030?
The base-case forecast is continued contraction, with no credible catalyst for a commercial rebound.
| Scenario |
2025-2030 outlook |
Probability assessment |
| Base case |
Flat at a negligible level or continued decline |
Highest |
| Re-entry by a generic manufacturer |
Limited regional supply without material global growth |
Low |
| Renewed clinical development |
No plausible commercial rationale |
Very low |
| Supply disruption for alternatives |
Temporary substitution in isolated markets |
Low and nonrecurring |
| Academic revival |
Small research use with no meaningful revenue effect |
Low |
A quantitative revenue projection would create false precision because public market datasets generally do not separate enflurane from broader volatile-anesthetic sales and do not report a dependable current baseline. The defensible projection is qualitative: no material global growth, no return to mainstream hospital use, and continued substitution by sevoflurane, isoflurane, desflurane, propofol, and regional anesthesia.
What could create upside for enflurane?
Potential upside factors are narrow:
- A shortage of competing volatile anesthetics
- Local procurement policies favoring legacy products
- Lower acquisition cost in markets with aging anesthesia equipment
- Use in countries where enflurane remains registered or stocked
- Research into historical anesthetic mechanisms
These factors could support isolated orders. They are insufficient to support a global re-commercialization thesis.
What generic entry risks exist for enflurane?
A generic sponsor would face low patent risk but meaningful execution risk.
Legal risk
Patent infringement risk is low because original exclusivity has expired and no material current Orange Book estate is apparent.
Regulatory risk
The sponsor would need to satisfy current FDA requirements for quality, labeling, manufacturing, container closure, and product performance. Historical approval does not eliminate present-day manufacturing obligations.
Commercial risk
Commercial risk is high because:
- Demand is low.
- Buyers may prefer established substitutes.
- Hospitals may lack current enflurane vaporizers or validated protocols.
- Suppliers may not achieve sufficient manufacturing scale.
- A low price may be required to displace incumbent products.
- Product discontinuation or shortage could make procurement unreliable.
The likely launch pattern would be a small, low-cost regional product rather than a high-value U.S. generic franchise.
What licensing deals and settlement agreements affect enflurane?
No current licensing transaction or patent settlement agreement has material relevance to enflurane’s commercial outlook. The original product was commercialized under historical corporate arrangements, but those arrangements do not create present-day exclusivity.
A new license could cover:
- Regional marketing rights
- Manufacturing technology
- Anesthesia-machine compatibility
- Legacy regulatory files
- Distribution rights
Such a transaction would be a supply or commercialization arrangement, not a conventional innovation licensing opportunity.
What is the investment outlook for enflurane?
Enflurane has little standalone pharmaceutical investment value. The principal value is defensive or operational:
- Access to a low-cost legacy anesthetic in selected markets
- Portfolio completion for a hospital-supply company
- Manufacturing utilization for a volatile-compound facility
- Backup supply during shortages
- Distribution in jurisdictions where alternatives are unavailable
It is not an attractive target for a conventional specialty-pharmaceutical investment thesis. There is no visible clinical catalyst, patent runway, premium-pricing opportunity, or differentiated delivery platform.
Key Takeaways
- Enflurane is a legacy inhalational anesthetic with no meaningful active clinical-development program.
- Its original patent and regulatory exclusivity have expired.
- No commercially relevant Orange Book patent barrier or Paragraph IV dispute is apparent.
- Formulation and manufacturing IP do not create a material current exclusivity position.
- The drug has been displaced by isoflurane, sevoflurane, desflurane, propofol, and regional anesthesia.
- Public data do not support a reliable standalone global revenue estimate.
- The 2025-2030 outlook is negligible or declining sales, with only limited regional or shortage-driven demand.
- Generic entry is legally feasible but commercially unattractive.
- Enflurane has no meaningful biosimilar risk because it is a small-molecule anesthetic, not a biologic.
- The main barriers are regulatory compliance, supply economics, equipment compatibility, and weak demand.
FAQs About Enflurane
Is enflurane still used in hospitals?
It may remain available in limited markets or institutional inventories, but it is not a mainstream anesthetic in major pharmaceutical markets.
Is enflurane FDA approved?
Enflurane was historically approved in the United States as Ethrane. Its historical FDA approval does not indicate an active current U.S. commercial franchise.
Can a company launch a generic enflurane product?
A company could pursue approval if it meets current regulatory and manufacturing requirements. The principal challenge is commercial viability rather than patent infringement.
Does enflurane have a biosimilar competitor?
No. Enflurane is a small-molecule volatile anesthetic, so biosimilar rules do not apply. Any follow-on product would be a generic or equivalent pharmaceutical product.
Why was enflurane replaced by sevoflurane and isoflurane?
Sevoflurane and isoflurane achieved stronger clinical and commercial positions because of differences in recovery, handling, adoption, supply, and perceived suitability for modern anesthesia practice. Enflurane’s seizure-like EEG activity, metabolism, and legacy status weakened its position.
References
-
ClinicalTrials.gov. (2025). Search results for enflurane. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=enflurane
-
U.S. Food and Drug Administration. (1998). Ethrane (enflurane, USP) prescribing information. FDA drug labeling archive.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. National Library of Medicine. (2025). Enflurane drug information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
-
World Health Organization. (2023). WHO model list of essential medicines: 23rd list. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
